Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mei Kadoya
Observed name:
MEI KADOYA
Institution:
Kanagawa Cancer Center
Observed institutions:
Yokohama City University Medical Center,
Yokohama City University Hospital,
Kanagawa Cancer Center,
Yokohama City University
ORCID:
0000-0002-2576-9946
Observed ORCID:
0000-0002-2576-9946
OpenAlex ID:
A5023205127
Effective Preparation of FFPE Tissue Samples for Preserving Appropriate Nucleic Acid Quality for Genomic Analysis in Thyroid Carcinoma
2024
·
Yoichiro Okubo
, Nagisa Toyama
, et al.
·
Endocrine Pathology
·
19
PDF
Clinicopathological analysis of thyroid carcinomas with the RET and NTRK fusion genes: characterization for genetic analysis
2024
·
Yoichiro Okubo
, Soji Toda
, et al.
·
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
·
14
PDF
The frequency of mutations in advanced thyroid cancer in Japan: a single-center study
2023
·
Soji Toda
, Hiroyuki Iwasaki
, et al.
·
Endocrine Journal
·
14
PDF
Association of BRAF or TERT Promoter Mutations and Advanced Papillary Thyroid Carcinoma
2024
·
SOJI TODA
, NAO SAITO
, et al.
·
Anticancer Research
·
6
Selpercatinib for treating recurrent mixed medullary and follicular cell-derived thyroid carcinoma: a case report
2024
·
Mei Kadoya
, Nobuyasu Suganuma
, et al.
·
Surgical Case Reports
·
5
PDF
Preoperative neoadjuvant targeted therapy with lenvatinib for inoperable thyroid cancer: Case reports and literature review
2022
·
Hiroyuki Iwasaki
, Soji Toda
, et al.
·
Medicine Case Reports and Study Protocols
·
4
Hyperthyroidism due to thyrotropin receptor antibody stimulation of metastatic thyroid carcinoma during lenvatinib treatment: a case report
2022
·
Soji Toda
, Mei Kadoya
, et al.
·
Annals of Palliative Medicine
·
4
PDF
Stepwise identification of an SQSTM1::NTRK3 fusion in papillary thyroid carcinoma: Diagnostic pitfalls and the value of integrative genomic profiling
2025
·
Yoichiro Okubo
, Mei Kadoya
, et al.
·
Pathology - Research and Practice
·
3
Neoadjuvant Chemotherapy With Selpercatinib for Locally Advanced RET Fusion‐Positive Papillary Thyroid Carcinoma: A Case Report
2025
·
Mei Kadoya
, Katsuhiko Masudo
, et al.
·
Case Reports in Endocrinology
·
2
PDF
Lenvatinib and selpercatinib successfully treated RET fusion gene-positive papillary thyroid carcinoma cardiac metastases: a case report
2023
·
Soji Toda
, Yayoi Yamamoto
, et al.
·
Gland Surgery
·
2
PDF
Real-World Genomic Characteristics and Prognostic Association in Advanced Papillary Thyroid Carcinoma
2026
·
Soji Toda
, Yukihiko Hiroshima
, et al.
·
JCO Precision Oncology
·
1
Efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated advanced thyroid carcinoma: Real world experience in 37 patients
2026
·
Haruhiko Yamazaki
, Nobuyasu Suganuma
, et al.
·
Endocrine Journal
·
1
Utility of RNA Sequencing and Immunohistochemistry for NTRK Fusion in Thyroid Carcinoma
2026
·
SOJI TODA
, RIKA KASAJIMA
, et al.
·
Anticancer Research
Panel-negative strategy for suspected fusion-driven papillary thyroid carcinoma
2026
·
Yoichiro Okubo
, Ikki Takada
, et al.
·
Thyroid Research
PDF
Histologic heterogeneity of primary and nodal lesions and intra-nodal comparative analysis after neoadjuvant selpercatinib in RET fusion–positive papillary thyroid carcinoma
2026
·
Chiaki Kanno
, Yoichiro Okubo
, et al.
·
Human Pathology Reports
Tumor response and thyroglobulin change in differentiated thyroid carcinoma treated with dabrafenib plus trametinib
2025
·
Haruhiko Yamazaki
, Nobuyasu Suganuma
, et al.
·
Cancer Chemotherapy and Pharmacology
PD-L1 expression in anaplastic thyroid carcinoma treated with lenvatinib
2023
·
Haruhiko Yamazaki
, Yoichiro Okubo
, et al.
·
Research Square
PDF
Show more works
View as search
Works count:
17
Citation count:
75
H-index:
5
I10-index:
3
Year
Topic
Type